Inhibitory Effects of Baicalein on the Influenza Virus in Vivo Is Determined by Baicalin in the Serum

被引:90
作者
Xu, Ge [1 ]
Dou, Jie [1 ]
Zhang, Lei [1 ]
Guo, Qinglong [2 ]
Zhou, Changlin [1 ]
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Dept Physiol, Nanjing 210009, Jiangsu, Peoples R China
关键词
baicalein; baicalin; antiviral activity; serum pharmacology; INTESTINAL 1ST-PASS METABOLISM; ACTIVE METABOLITE; FLAVONOIDS; REPLICATION; AMANTADINE; RHEIN;
D O I
10.1248/bpb.33.238
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Baicalein, an extract from Scutellaria baicalensis, was evaluated for its ability to inhibit the influenza virus in vivo. Oral administration of baicalein to BALB/c mice infected with the influenza A/FM1/1/47(H1N1) virus showed significant effects in preventing death, increasing the mean time to death, inhibiting lung consolidation, and reducing the lung virus titer in a dose-dependent manner. These effects are believed to be due to baicalin, the metabolite of baicalein in the serum. At a concentration of baicalin 2 mu g/ml in overlay medium, it showed significant inhibition in the plaque assay, and the mean IC50 value of baicalin was calculated as 1.2 mu g/ml in the cytopathic effect assay. Our results showed that baicalein warrants further research as a potential antiinfluenza viral agent.
引用
收藏
页码:238 / 243
页数:6
相关论文
共 35 条
[1]  
ABE K, 1990, CHEM PHARM BULL, V38, P208, DOI 10.1248/cpb.38.208
[2]  
CAI YW, 2007, J US CHIN MED SCI, V4, P51
[3]  
Cheng Y, 2006, WORLD J GASTROENTERO, V12, P5153
[4]   Human cytomegalovirus-inhibitory flavonoids: Studies on antiviral activity and mechanism of action [J].
Evers, DL ;
Chao, CF ;
Wang, X ;
Zhang, ZG ;
Huong, SM ;
Huang, ES .
ANTIVIRAL RESEARCH, 2005, 68 (03) :124-134
[5]  
Fleming DM, 2001, INT J CLIN PRACT, V55, P189
[6]  
FREDERICK GH, 1990, ANTIVIR RES, V14, P25
[7]  
[龚明涛 GONG Mingtao], 2008, [中国药学杂志, Chinese Pharmaceutical Journal], V43, P1332
[8]  
[郭晓宇 GUO Xiaoyu], 2008, [中国药学杂志, Chinese Pharmaceutical Journal], V43, P524
[9]  
HAYDEN FG, 1992, CURR TOP MICROBIOL, V176, P119
[10]  
Huang Yu, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P177, DOI 10.2174/1568006043586206